Dr. Pei Lin, MD

Dr. Lin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Lin's NPI, 1912004680, was assigned on September 17, 2006. Dr. Lin graduated from Nanjing Medical University in 1982. Dr. Lin's Texas license number on file is L6497.

Dr. Lin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Lin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Lin is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 2 sites in all. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Lin is board certified in anatomic pathology & clinical pathology by the American Board of Pathology. Dmand AI has Dr. Lin's licenses on file in 4 states: Texas, California, Michigan and Arkansas.

CMS data shows 1,530 Medicare services from Dr. Lin across 14 procedure codes in 2024, for 352 Medicare patients. Medicare paid $43,542 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 352 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 181 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 68, with 49% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 163 papers to Dr. Lin, published from 2005 to 2025. 2018 was the busiest year, with 10. The most frequent topics are Multiple Myeloma, Immunophenotyping and Biomarkers, Tumor. Dr. Lin has published most often in Am J Clin Pathol. Dr. Lin's most frequent co-authors are Leonard Jeffrey Medeiros, MD, Shaoying Li, MD and Guilin Tang, MD.

CMS Open Payments shows 28 general payments to Dr. Lin from 9 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 61% of the total. Abbvie Inc. paid the most, $6,400.

Dr. Lin graduated from Nanjing Medical University in 1982.

Dr. Lin is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.